Cart
sales@molnova.com
1-Linoleoyl Glycerol
CAS No. 2277-28-3
1-Linoleoyl Glycerol( 1-Linoleoyl-rac-glycerol | Glyceryl monolinoleate | Monolinolein | Glycerol 1-monolinolate )
Catalog No. M26010 CAS No. 2277-28-3
1-Linoleoyl Glycerol is fatty acid glycerol that has been isolated from Saururus Chinensis roots.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 26 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name1-Linoleoyl Glycerol
-
NoteResearch use only, not for human use.
-
Brief Description1-Linoleoyl Glycerol is fatty acid glycerol that has been isolated from Saururus Chinensis roots.
-
Description1-Linoleoyl Glycerol is fatty acid glycerol that has been isolated from Saururus Chinensis roots. The (R)-1-Linoleoyl Glycerol and (S)-1-Linoleoyl Glycerol exhibit Lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitory activities with IC50 values of 45.0 and 52.0 μM, respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms1-Linoleoyl-rac-glycerol | Glyceryl monolinoleate | Monolinolein | Glycerol 1-monolinolate
-
PathwayMetabolic Enzyme/Protease
-
TargetPhospholipase
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2277-28-3
-
Formula Weight354.531
-
Molecular FormulaC21H38O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 100 mg/mL (282.07 mM)
-
SMILESCCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(O)CO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Fujino H, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003 Jan;33(1):27-41.
molnova catalog
related products
-
Uric Acid
An oxidation product, via xanthine oxidase, of oxypurines such as xanthine and hypoxanthine.
-
Varespladib
Varespladib (LY315920) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM. Phase 3.
-
Rilapladib
A potent, selective and oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.23 nM.
